| Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study T Dahlén, G Edgren, M Lambe, M Höglund, M Björkholm, F Sandin, ... Annals of internal medicine 165 (3), 161-166, 2016 | 110* | 2016 |
| An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk T Dahlén, M Clements, J Zhao, ML Olsson, G Edgren Elife 10, e65658, 2021 | 38 | 2021 |
| Measurable health effects associated with the daylight saving time shift H Zhang, T Dahlén, A Khan, G Edgren, A Rzhetsky PLoS computational biology 16 (6), e1007927, 2020 | 35 | 2020 |
| Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving … T Dahlén, M Kalin, K Cederlund, A Nordlander, M Björkholm, P Ljungman, ... European Journal of Haematology 96 (2), 175-180, 2016 | 29 | 2016 |
| Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era–a report from the Swedish CML register S Söderlund, T Dahlén, F Sandin, U Olsson‐Strömberg, M Creignou, ... European journal of haematology 98 (1), 57-66, 2017 | 25 | 2017 |
| Estimating heritability and genetic correlations from large health datasets in the absence of genetic data G Jia, Y Li, H Zhang, I Chattopadhyay, A Boeck Jensen, DR Blair, L Davis, ... Nature Communications 10 (1), 5508, 2019 | 21 | 2019 |
| Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population‐based Swedish chronic myeloid leukaemia registry H Flygt, F Sandin, T Dahlén, A Dremaine, A Lübking, B Markevärn, ... British journal of haematology 193 (5), 915-921, 2021 | 17 | 2021 |
| Neutrophil‐to‐lymphocyte ratios in patients undergoing aortic valve replacement: the PARTNER trials and registries B Shahim, B Redfors, BR Lindman, S Chen, T Dahlen, T Nazif, S Kapadia, ... Journal of the American Heart Association 11 (11), e024091, 2022 | 15 | 2022 |
| Risk of hematological malignancy in blood donors: a nationwide cohort study Z Jingcheng, D Torsten, B Anne, E Gustaf Transfusion, 2020 | 13 | 2020 |
| Intracerebral hemorrhage among blood donors and their transfusion recipients J Zhao, K Rostgaard, E Lauwers, T Dahlén, SR Ostrowski, C Erikstrup, ... JAMA 330 (10), 941-950, 2023 | 12 | 2023 |
| Increased risk of cardiovascular events associated with TKI treatment in chronic phase chronic myeloid leukemia. Data from Swedish population-based registries T Dahlén, G Edgren, M Höglund, M Lambe, M Björkholm, F Sandin, ... Blood 124 (21), 3134, 2014 | 12 | 2014 |
| The frequency of misattributed paternity in Sweden is low and decreasing: A nationwide cohort study T Dahlén, J Zhao, PKE Magnusson, Y Pawitan, J Lavröd, G Edgren Journal of internal medicine 291 (1), 95-100, 2022 | 10 | 2022 |
| Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide … T Dahlén, G Edgren, P Ljungman, H Flygt, J Richter, U Olsson‐Strömberg, ... American Journal of Hematology 97 (4), 421-430, 2022 | 8 | 2022 |
| Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study J Zhao, T Dahlen, G Edgren Vox sanguinis 116 (5), 581-590, 2021 | 7 | 2021 |
| Cost effectiveness of the third-generation tyrosine kinase inhibitor (TKI) ponatinib, vs. second-generation TKIs or stem cell transplant, as third-line treatment for chronic … C Hirt, S Iannazzo, S Chiroli, LJ McGarry, P le Coutre, L Stenke, T Dahlén, ... Applied Health Economics and Health Policy 17, 555-567, 2019 | 6 | 2019 |
| A population‐based, retrospective cohort study of the association between ABO blood group and risk of COVID‐19 T Dahlén, H Li, F Nyberg, G Edgren Journal of Internal Medicine 293 (3), 398-402, 2023 | 5 | 2023 |
| The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study T Dahlén, H Flygt, A Lübking, U Olsson-Strömberg, L Wennström, ... Leukemia 37 (5), 1156-1159, 2023 | 3 | 2023 |
| Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence T Dahlen, C Kockerols, G Ferreira, PE Westerweel, J Mayer, T Sahmoud, ... Blood 138, 1485, 2021 | 2 | 2021 |
| Overall survival and adverse events in 378 ibrutinib-treated patients with chronic lymphocytic leukemia-a Swedish register-based nationwide study T Dahlen, G Edgren, L Stenke, J Zhao Blood 138, 3750, 2021 | 1 | 2021 |
| Frequency of comedication of proton pump inhibitors with crystalline dasatinib in chronic myeloid leukemia and effects on TKI-bioavailability. T Dahlén, G Larfors, H Lennernäs, C Liljebris, M Von Euler, M Brisander, ... Journal of Clinical Oncology 42 (16_suppl), 6561-6561, 2024 | | 2024 |
Gustaf EdgrenAssociate professor, Karolinska Institutet在 ki.se 的电子邮件经过验证
